Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
暂无分享,去创建一个
M. Mohty | P. Moreau | C. Touzeau | C. Chabannon | T. Facon | A. Perrot | C. Hulin | D. Caillot | F. Heshmati | B. Hébraud | F. Malard | C. Mariette | T. Kanouni | D. Lebon | Z. Van de Wyngaert
[1] H. Goldschmidt,et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] D. Hose,et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE , 2020, Leukemia.
[3] M. Mohty,et al. Management of patients with multiple myeloma during the COVID-19 pandemic , 2020, The Lancet Haematology.
[4] J. Emparanza,et al. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield , 2019, International journal of laboratory hematology.
[5] J. Duyster,et al. Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers , 2017, Leukemia & lymphoma.
[6] H. Goldschmidt,et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[7] M. Drayson,et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. , 2016, The Lancet. Haematology.
[8] S. Devlin,et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study , 2016, Bone Marrow Transplantation.
[9] B. Barlogie,et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] A. Nademanee,et al. Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma , 2013, American journal of hematology.
[11] D. Atanackovic,et al. Second autologous transplant as salvage therapy in multiple myeloma , 2013, British journal of haematology.
[12] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[13] F. Awan,et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy‐era with plerixafor and G‐CSF has superior efficacy but significantly higher costs compared to mobilization with low‐dose cyclophosphamide and G‐CSF , 2013, Journal of clinical apheresis.
[14] A. Nademanee,et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.
[15] R. Arranz,et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone , 1997, Bone Marrow Transplantation.
[16] L. Schwartzberg,et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.
[17] Michael L. Wang,et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.